ORGN 3 |
| The c-Jun N-terminal protein kinase 3 (JNK3) has been implicated in several neurodegenerative diseases such as Alzheimer's, Parkinson's and stroke. Inhibition of JNK3 with small molecules that complete with the binding of ATP provides a potentially useful method of treatment for these diseases. Several compounds have recently been reported to successfully inhibit JNK3, however the selectivity of these compounds has been insufficient for clinical use. We have recently developed an efficient synthetic sequence based on a rhodium catalyzed annulation via selective C-H bond activation allowing for the generation of a known JNK3 inhibitor and ready access to a number of derivatives difficult to obtain by other means.
|
|
Metal-Mediated Reactions and Syntheses
8:00 AM-12:00 PM, Sunday, 10 September 2006 Moscone Center -- Room 134, Oral
Division of Organic Chemistry |
